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Abstract
Spontaneous regression or remission (SR) of cancers has been
defined as the disappearance of the malignancies without any
treatment or with obviously inadequate treatment. Four case reports
are presented. These include a case of pleomorphic liposarcoma
with bilateral lung metastases, a case of recurrent squamous cell
carcinoma of the esophagus followhg esophagectomy a year
earlier, a case ofa squamous cell carcinoma of the scalp, and a case
of a ruptured hepatocellular carcinoma with an emergency right
hepa tic lobectomy but with some gross cancer remaining in the left
hepatic lobe.
The literature of SR of cancers was reviewed and various mecha
nisms possibly Thvolved in the disappearance of the cancers were
discussed. Although immune modulation has been stated to be the
most likelyprocess causing SR, other mechanisms, such as genetic
therapy, withdrawal of carcinogens, infection, fever and vaccine
roles, apoptosis, antibody, antiangiogenesis andmaturation mecha
nisms, withdrawal of therapy, natural killer activity, endocrine,
hormonal, and pregnancy factors, and prayers or psychoneuro
religious participation were also mentioned. Induction and inhibition
of malignant protein expression and repair of gene damage may
prove to be the more important processes in cancer regression.
It was also pointed out that the pulmonary metastases of the
liposarcoma and the recurrent squamous cell carcinoma of the
esophagus may be the very first cases of their kind to be described
and that it is rare indeed to find 4 cases of SR’s in a solo practice.
Finally, it is likely that SR is rarer than previously believed and that
the incidence may be one in every 140,000 cases of cancer rather
the one per 60,000 to 100,000 cancer cases as earlier thought.
Introduction
Spontaneous regression or remission (SR) of cancers has been
defined by Everson and Cole1 as the complete or partial, permanent
or temporary disappearance of all or at least a significant portion of
a well diagnosed malignant tumor in the absence of all treatment or
in the presence of therapy which is considered inadequate to exert a
significant influence on the neoplastic disease. Remissions are
supposed to last at least one month and should not just be the waxing
and waning of stable disease. This definition of SR is considered
unequivocal for cancer regression with no medical therapy, treat
ment failure, or therapy known to be failures.
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The true incidence of SR is unknown, but Cole2 has estimated that
probably it occurs in no more than once in 60,000 to 100,000 people
with cancer. After a review of a large number of cases, Cole was able
to document only 176 cases from 1900-1964. Lymphomas and
leukemias were not counted. Therefore, if one SR occurs, on an
average, in about 80,000 persons with cancer, it would require a
single surgeon working about 30 years and seeing about 10,000
cases of cancer a year, before he would find 4 spontaneous regres
sions. But if only one SR occurs in 140,000 cancerous cases, a
surgeon would need to see nearly 19,000 cases of cancer a year for
30 years, or a total of 570,000 cancer cases, before he would find 4
cases of SR.
Nearly two thirds to three fourths of all SR’s occurred in just a few
types of cancers. Furthermore, most soft tissue sarcomas occurred
earlier this past century and have been difficult to find in recent
literature. Even with the extensive review by Everson and Cole,’
only eleven cases of soft tissue sarcomas with SR were recorded.
None were pleomorphic or dedifferentiated liposarcomas.
After a current check of more than 1200 citations and references
in a literature search, it was hard to find any cases of regression of
metastatic pleomorphic liposarcoma to the lungs and of recurrent
squamous cell carcinoma of the esophagus. There was a case of
spontaneous remission of lung metastases from an esophageal
primary but the primary esophageal lesion did not regress except
only partially.’°° Furthermore, SR also seemed to occur much less
frequently than previously thought and was found to occur at a rate
of 1 per 140,000 cases of cancer.
Because of the extreme rarity of finding 4 cases of SR in a solo
practice of a surgeon and because the patients with metastatic
pleomorphic liposarcoma and recurrent esophageal squamous cell
carcinoma may be the first cases of their kind to be reported, this
paper is being presented with the 4 case reports, review of the
literature, and a discussion of possible mechanisms involved in SR.
First Case Report
Mrs. A. T., 69-year-old part-Hawaiian and part-Caucasian woman,
noted a 3.0 cm rounded, tender mass in the left gluteal area after a
fall in late 1996. X-rays and sonograms showed a homogeneous soft
tissue density, 5.0 x 5.2 cm, with well-defined margins in the left
gluteal region suggestive of a hematoma. The lesion slowly in
creased in size and, therefore, surgical consultation was sought in
December 1997. Except for the left gluteal mass, her physical
examination was unremarkable.
MRI study of the left gluteal region showed an 8.0 cm soft tissue
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mass involving the fat overlying the left gluteus maximus muscle
without definite invasion of muscle. Excision biopsy of the lump
was done on 01/09/98. With the exception of transient atnal fibril
lation, she did well. The histological examination of the 12.0 cm x
7.0 cm lesion showed a high-grade pleomorphic liposarcoma. A
surgical margin was focally involved. Subsequently, wide radical
re-excision, including portions of the left gluteus maximus muscle,
was carried out. Pathology examination revealed no evidence of
residual sarcoma. She was seen in consultation by a medical oncolo
gist and a radiation therapist. The latter subsequently delivered
6,480 rads to the left gluteal area.
Because of some necrosis involving the edges of incision, these
areas were excised on 01/24/98. During the course of her therapy,
studies revealed a lower left neck mass which required a left thyroid
lobectomy on 02/25/98. Pathological examination noted an occult
papillary carcinoma, 0.1 cm in greatest microscopic dimension
without capsular or surgical margin involvement, associated with a
multinodular goiter.
On 03/03/98, a large left hip seroma was drained by the insertion
of two Jackson-Pratt drains. After the drains became plugged, the
seroma reaccumulated, requiring frequent aspirations-drainage.
Because of the persistent recurrence of the seroma, 250 mg of
Doxycycline liquid was injected into the cavity in an attempt to
sclerose the area and allow adherence of the walls of the cavity. But
this caused the injection site to become necrotic and an area 1.0 cm
in size to blackened. An eschar developed at the site. Furthermore,
the seroma persisted.
On 09/03/98, chest x-ray showed a 3.0 cm mass in the anterior
segment of the upper lobe of the right lung, a 1.0 cm mass in the
lower lobe of the left lung, and a 3.0 to 4.0cm mass in the left hilum
(Fig 1 a). CT scan of the chest, on 09/10/98, confirmed the presence
of these masses.
MRI studies of the left gluteal region on 09/16/98 showed only
post-operative changes of the subcutaneous tissue. There was an
encapsulated fluid collection or seroma in the operative site.
On 09/17/98, a CT guided needle biopsy of the left hilar mass was
done. Pathological studies revealed malignant neoplasm, consistent
with metastasis from the previously resected high-grade sarcoma of
the left gluteal area (Fig 2a).
Before any new therapy could be given for the metastases to the
lungs, another chest x-ray on 10/02/98 showed a decrease in the size
of the pulmonary and left hilar metastases. Subsequent chest x-rays
on 11/02/98 and 12/02/98 showed further regression of the lung and
the hilar metastases. A CT scan of the chest on 05/14/99 and a chest
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x-ray on 05/23/99 (Fig ib) and on 08/02/99 revealed complete
regression of all the metastases with no treatment at all.
On 08/11/99, excision of the left hip irradiated tissues, the eschar
or necrotic injection site, and the pseudocapsule of the serous cavity
were excised. Advancement of skin flaps were done for closure.
Chest x-rays on 08/07/00 continued to show no evidence of me
tastases.
Comment
The evidence for spontaneous regression in this case is convincing.
Histologically proven lung metastases disappeared with no therapy
at all.
Second Case Report
Mr. M. S., a 57 year old Japanese man, had a near total gastrectomy,
omentectomy, splenectomy. resection of the distal one third of the
pancreas, jejunojejunostomy. and a feeding jejunostomy on 02/11/
83 for a moderately well differentiated adenocarcinoma of the
stomach superficially invading the underlying muscular layer. On
03/03/83. he had drainage of a left subphrenic abscess. Subse
quently. he did well.
On 05/09/89, on aroutine follow-up esophagogastroduodenoscopy,
a 3.0cm reddened area in the lower esophagus, 2.0 to 3.0 cm above
the esophagogastric junction, was biopsied. The pathology report
was squamous cell carcinoma of the lower esophagus. On 05/15/89,
the patient underwent a resection of his gastric remnant and the distal
third of his esophagus. An end-to-side esophagojejunostomy, side to
side jejunojejunostomy and a feeding tube jejunostomy were also
done.
Post-operatively, on 05/25/89, a gastrografin swallow showed a
leak of the esophagojejunostomy site with communication to the left
pleura space. On the same day. a tube was placed in the left chest to
drain the empyema. During the placement of the chest tube, the
patient aspirated some gastric contents and developed pneumonia.
On 06/07/89. a tracheostomy was done. The chest tube was discon
tinued subsequently when the patient recovered. The final pathol
ogy report showed moderately well differentiated squamous cell
carcinoma of the distal esophagus invading the submucosa but not
involving the muscularis.
On 05/24/90, a year later, endoscopic biopsy of a 1.0 cm lesion at
the esophagojejunal junction revealed recurrent squamous cell
carcinoma. Five pathologists in three different hospitals in Hono
lulu, Hawaii, concurred that the patient had recurrent squamous cell
carcinoma (Fig 2b). Consultants recommended further resection or
radiation of the carcinomatous area. However, before any further
therapy could be started, another endoscopy with biopsy done on
05/31/90 showed only severe inflammation. Repeated endoscopic
biopsies done yearly from 1990 until 1998 did not reveal any
recurrent squamous cell carcinoma. His last endoscopy and biopsy
on 09/07/99 also showed no recurrent carcinoma and only a mild
chronic inflammation of the esophagojejunal junction. He has
remained free from his recurrent carcinoma without any treatment
for at least 9 years.
Comment
Endoscopic biopsies were done a week apart in this case. The 05/24/
90 biopsy showed recurrent squamous cell carcinoma while the 05/
31/90 biopsy showed only inflammation. When subsequent endo
scopies and biopsies showed no cancer, the original slides were
reviewed and re-reviewed by three different pathologists at St.
Francis hospital, by a Dr. H.N., from Queen’s Hospital who wrote
a formal consultation confirming the recurrent cancer, and by a Dr.
G.S. from Kuakini Hospital at a presentation during a tumor confer
ence. All agreed that there was recurrent squamous cell carcinoma
of the esophagus.
While regression in squamous cell carcinoma in the esophagus is
unusual and this may be the first reported case of SR in a recurrent
esophagus cancer, remission in a week would be rare, but there have
been other cases of other cancers that have regressed rapidly. SR is,
after all, a remarkable phenomenon. Why it should even occur is
certainly unknown.
Figure 2b. Slide shows recurrent squamous cell carcinoma of
the esophagus.
Third Case Report
Mrs. M. K., an 87-year-old Chinese woman was seen on 08/11/95
because of two large necrotic lesions on her forehead and scalp. The
one on the forehead was ulcerated, 2.0 x 4.0 cm in diameter, and
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umbilicated. On the vertex of the scalp was another similar 6.0 x 8.0
cm lesion that seemed infected. Past medical history revealed
hypertension, end-stage renal disease, left ventricular hypertrophy,
congestive heart failure, previous staphylococcus sepsis, gastric
ulcers, altered mental status, pancytopenia. and multiple thrombec
tomies of clotted Gore Tex grafts required for hemodialysis.
On 09/08/95, an excision of the 4.0-cm ulcerated lesion on the
forehead was done. Undermining of the scalp with a rotation flap
graft was performed to close the defect. Biopsies of the larger 8.0cm
lesion on the vertex of her scalp were taken. Both areas were
diagnosed as squamous cell carcinomas of the scalp (Fig. 2c). She
was seen by a radiotherapist for treatment of the larger squamous
cell carcinoma involving the vertex of the scalp. However, because
the patient was uncooperative, no radiation or further treatment was
initiated.
On 0 1/29/96, about 5 months later, the scalp lesion started to
disappear. The areas that were once ulcerated, necrotic, and crusted
now seemed smoother although somewhat reddened. By early May
1996, the squamous cell lesions of the scalp had completely and
spontaneously regressed without any treatment. The scalp now
looked normal without any redness. She remained free of cancer
without any treatment until 12/14/98, when at age 91 years, she
expired from staphylococcus aureus sepsis.
Comment
Although no repeat biopsy was done during the three years of
remission, the scalp of this patient, from early May. 1996, was
completely normal to physical examination and to all observers. It
would have been excessive to have done a biopsy to prove that the
normal skin was normal. Besides, the family was reluctant to even
bring the patient to the office for follow-up as there no longer was
any abnormality on her scalp. It would have been very difficult to
justify another biopsy since even an office visit was considered
unnecessary by her family.
Fourth Case Study
Mr. J. C., a 53 year old Chinese man from Tahiti, was seen on 04/14/
70 because of an enlarging mass in his right upper abdomen.
Examination, at that time, suggested a hepatocellular carcinoma.
His past medical history revealed a Billroth II gastrectomy for a
large benign gastric ulcer and cirrhosis of the liver in August of
1966.
Just prior to his scheduled laparotomy. he became hypotensive
and was rushed into surgery. A large ruptured hepatocellular carci
noma in the right lobe of his cirrhotic liver was uncovered. Hemo
peritoneum was evident. The cancer extended into the medial
segment of the left lobe of the liver. Because of the emergency nature
of the operation. the hypotension, and the cirrhosis of the liver, only
a rapid right hepatic lobectomy was done. Gross cancer was left in
the left lobe of the liver. Recovery was fortunately rapid and the
patient was discharged on 04/21/70. 7 days after surgery.
Subsequently, he was given 5-fluorouracil weekly for a month
but, because the patient wanted to return to Tahiti. further chemo
therapy was not given. He. however, survived for 21 years more
without any known definitive therapy. The patient was last exam
ined in May 1987. in Honolulu. at which time, he was found free of
cancer. He survived 21 years and died on 02/02/91 in Tahiti with no
evidence of recurrence of his hepatocellular carcinoma. The cause
of his death was stated to be a stroke.
Comment
The pathological examination revealed the right lobe of the liver
with a large ruptured hepatocellular carcinoma. The cancer had
extended to and had involved the resected margin. Gross cancer was
noted at the margins of resection on the specimen and on histological
examination. At surgery, the cancer had invaded the left lobe of the
liver. There were also nodules of cancer present in the left liver.
Though cancer was left in the margin and elsewhere in the left lobe
of the liver, this patient survived 21 more years without further
treatment.
Review of literature and discussion of possible
mechanisms involved in spontaneous regres
sion of cancer.
Incidence
In a recent literature search for reports of complete spontaneous
regressions of cancer, more than 1200 citations and references were
secured. These involved papers from the 1970’s until the present. In
addition, a large number of articles and books published before 1970
were also reviewed. The largest number of references involved
instances of SR in leukemias4’56789 and lymphomas.’°”’2’3”415
Because of the inconsistency and variability of the SR’s in the
leukemias and lymphomas,2’3Everson and Col& chose not to
include them in their description of the 176 cases of SR found
between 1900 and 1964. Why leukemias and lymphomas display
this inconsistent and variable behavior is unknown. Why they
should form such a relatively large group so as to consist of more
than 50% of the reports of SR is also unknown.
Besides the 176 cases found between 1900 and 1964 by Everson
and Cole,1 another 188 cases of SR found between 1966 and 1985
were reported by Baker.84 However. Challis and Stam69 indicated
that, between 1966 and 1987, there were 504 cases of SR. They
included lymphomas and leukemias in their total.
A search of the literature for SR’s of cancer between 1986 and
2000 revealed another 139 new cases. Partial regressions or cases
not well documented or histologically proven were not included.
Lymphomas, leukemias, renal cell carcinomas, and melanomas
again formed the majority or 67.6%. There were 43 cases of renal
cell carcinoma and 18 cases of melanoma.
If these 139 cases were added to the 176 cases ofEverson and Cole
found between 1900 and 1964 and the 188 cases of Baker, found
between 1966 and 1985, there would be a total of 503 cases of SR
last century. But if the 504 cases of Challis and Stam were to be
added to the 176 cases of Everson and Cole and to the 139 new cases.
there would be 819 of SR’s of cancers during the past century
instead.
Parkin has stated that the estimate of new cancer cases for the
year 1990 for every country in the world was 8.1 million. This
number. however, excluded non-melanoma skin cancers. One half
of the total cancers occurred in developing countries.
During 1994. 1.208.000 new cases of cancer were diagnosed in
the United States.95 In the mid 1990’s hepatocellular carcinoma.
probably the most common cancer in the world was estimated to he
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over 1,000,000 cases yearly, and all cancer in the United States
generally to be about 1,350,000 cases.96In Grunlee’ s article,’0there
was a forecast made of the number of cancer cases expected to be
diagnosed in the US in the year 2000. This number was 1,220,100.
Most will be lymphomas (62,300 cases) and leukemias (30,800
cases). Esophageal carcinomas will constitute 12,300 cases and soft
tissue malignancies 8,100.
Roughly, the number of cancer cases in the U.S. would be
19.500,000 in the period between 1985 and 2000. This would make
an estimate of about 1 case of SR for every 140,000 cases of cancer,
making the number of SR’s in the U.S. even rarer than originally
believed by Everson and Cole2 who wrote that SR’s occurred 1 in
60,000 to 100,000 cancer cases or by Baker84 who thought that SR
probably occurred more frequently.
The next 3 cancers with frequent numbers of SW shave been renal
cell ‘““ neuroblastomas,’9’20:”36and malignant mela
nomas.”22’348They form the largest group of solid cancers known
to have spontaneous regressions. Of the solid tumors, renal cell
carcinomas seem to behave like leukemias with their regressions
and recurrences.’6”7
Other solid cancers with anecdotes of spontaneous regression
have also been described. Although of quite rare occurrences, lung
cancers,”27’832798°epidermoid cancer of the bronchus,78hepatocel
lular carcinomas,”25632choriocarcinomas37bladder malignancies,35
soft tissue and bony sarcomas,’ prostate cancer,32 colon and rectal
cancers,”32 malignancies of the ovary.32 breast,32’4testis,39 uterus,’
bladder,32’47stomach,3’292larynx,”32thyroid.” tongue,’ pancreas,’
and esophagus,3OOhave been described with SR’s.
By comparison with the leukemias and lymphomas, the solid
tumors have indeed been few and mention in recent literature of
these solid cancers have been sparse. Is there a factor or factors that
allow leukemias and lymphomas to spontaneously regress so much
more frequently than, say. pleomorphic liposarcomas. or esoph
ageal squamous cell carcinomas?
Possible mechanisms involved in spontaneous
remission
Documented reports of complete spontaneous remissions ofcancers
are unusual, if not remarkable. Generally, regressions of cancers
have tended to occur in lymphomas. leukemias, kidney cancers,
neuroblastomas, and melanomas. There have been suggestions of
“natural killing activity” in lymphomatous patients with regres
sions,5’ and viral or bacterial infections causing enhancement of
immune systems.88’99°Cytokine release and cellular immune acti
vation causing apoptosis, differentiation of malignant tumors into
benign ones. angiogenesis inhibition, genetic factors, and telomerase
inhibition all have been mentioned as possible mechanisms in
promoting spontaneous
Factors that may cause or be associated with SR have been listed
elsewhere also.”2”3’7328These involve modulations, modifi
cations. manipulations or stimulations of the immune sys
te2”9’3301784526°with the use of various substances as vac
cines.40952 toxins.3’ interleukins and interferons. 3,,45,46,63,M In
addition, transfusions,5’67enzymes,42gene therapy.93feverand infec
tions,5’14”3042 trauma or operations,67 endocrines or hormones or
pregnancy influences,47’53-181 elimination of carcinomas or irri
tants67’maturation or differentiation,48’cytotoxic or natural killer
cells with lytic activity against tumor cells lines,’8’1951472 with
drawal of therapy,55’6psychoneuro-spiritual immunologic factors,
3l,32,67,68,69,70,7 and angiogenesis therapy66 have all been cited as
playing roles in the regression of cancer.
Cytokines.3’59608especially interleukin. appear to play an important
part in tumor regression causing necrosis and apoptosis.57’65 The
latter effect can also be induced by cysteine proteases,58thus leading
to spontaneous tumor regression in rat histiocytomas.
Immunological mechanisms:
Interleukin has been used effectively to inhibit cancer growth.3’85SR
is thought to be the result of an efficient immune response against
melanoma cells in vivo critically influenced by a complex network
of interacting cytokines present.57’83Viral infections inducing host
production of interferon with inhibition of tumor by interferon have
been thought to be mechanisms for SR.8 The normalization of
OKT4/OKT8 ratio may be a factor in cancer regression as suggested
by Ribera8 and Hansen49.
Chromosomal or genetic mechanisms:
Chromosomal or genetic abnormalities5’6910347475768have been
evident in cancer for some time. There has been also some informa
tion indicating that chromosomal manipulation such as deletion and
enzymatic blockage74 can cause remission.
DNA damaged by radiation or tobacco smoke can result in
mutations commonly found in human cancers, such as lung carcino
mas. Spontaneous oxidation of guanine residues in DNA generates
8-oxoguanine (oxoG). By mispairing with adenine during replica
tion. oxoG gives rise to a G-C to T-A transversion, a frequent
somatic mutation in human cancers.
A mending enzyme called 8-oxoguanine DNA glycosylase
(hOGG 1) can repair the damaged DNA by catalyzing the expulsion
of damaged DNA. This is accomplished by cleavage of the DNA.
thus cutting away the problem part (oxoG) with chemical reactions.
What is cut out is a single letter of the genetic code. one of some 3
billion letters arranged in pairs to form an estimated 100,000 genes
in humans.
The protein (hOGG1), a natural antioxidant, has been noted to
pocket the damaged letter known as 8-oxoguanine (oxoG) which
had resulted from free radical oxidation caused by carcinogens and
to repair the damage to the DNA.
What is also interesting is the observation that partial or complete
loss ofhOGGl has been linked in 60-70% of all lung malignancies.
In these latter cancers, one of the genes for making hOGG1 has been
deleted and, in small cell carcinoma which has a dismal prognosis.
there was a complete loss of hOGG I
Genetic enzymatic inhibition
Recent preliminary data’°2have indicated that an Abi tyrosine kinase
inhibitor has significant activity in chronic myelogenous leukemia
(CML) even in those patients that interferon therapy has not helped.
The consequence of the translocation of 2 genes, resulting in the
Philadelphia chromosome, is the creation of a fusion protein Bcr
Abl which directs the production of activated tyrosine kinase. The
latter promotes the chaotic proliferation of white blood cells in the
bone marrow.
A designed agent, labelled STI 571, has been used to inhibit the
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Abi kinase in CML and has had quite impressive complete hemato
logic responses in Phase 1 studies.
Gene switching
One of the more recent, interesting researches involving regressions
ofcancers has involved the “switching off and on of cancer” in mice.
By putting the antibiotic tetracycline in the drinking water of
leukemia stricken mice, even advanced stages of the leukemia
disappeared. But when the antibiotic-spiked water was withdrawn.
the cancer returned.
The mechanisms apparently involved the 2 genes, Bcr and Abl.
Fusion would occur in a process called chromosomal translocation
whereby the 2 genes fused when they were out of their normal
positions on chromosomes. Inside a cell, the fused genes Bcr-Abl
would direct production of tyrosine kinase. This enzyme would
promote a chaotic proliferation of white blood cells in the bone
marrow thus resulting in leukemia.
Given the tetracycline, these mice would switch off the gene and
its leukemia-producing activity. Cancer cells then would stop repro
ducing and would begin to die. Cancer reversal in some animals have
been induced as much as three times.
Tetracycline in mice and tyrosine kinase inhibiting drugs in
humans can inhibit leukemia generation but they do not eliminate
the fused Bcr-Abl. If resistance to the inhibitor develops, either
species will relapse with leukemia.93
New Approaches
New approaches which attack the molecular mechanisms by which
the tumor gets its blood supply and hence its growth factors and
oxygenation have been described.’04It is quite well known that the
greater the amount of vascular endothelial growth factor (VEGF)
present in a cancer, the more rapid the tumor growth. VEGF,
produced by a gene isolated by Genentech’ s Napoleone Ferrara, is
critical for the production of blood vessels. Embryos with defective
VEGF genes die before birth because of the failure to grow normal
blood vessels, evidence for the role of VEGF as a key player.
Molecular biologists Peter Hirth and Gwen Fyfe of Sugenl
Phannacia Corporation have tried to deactivate the receptor sites of
VEGF, whereas Genentech has designed a monoclonal antibody to
VEGF that slowed tumor growth in animals by preventing VEGF
from docking with its receptor. These antibodies are engineered
versions of natural immune system fighters that attack a particular
target. Clone systems, a New York company. has also entered the
fray with a designed antibody against VEGF that it hopes will be
more potent than that of Genentech’s. Novartis and Astra-Zeneca
are also testing drugs to block VEGF.
This idea of starving tumors by antiangiogenesis has been attrib
uted to Judah Volkman whose effort with Entremed in Rockville,
Maryland, targeting angiostatin and endostatin seems less advanced
than the VEGF research.
Still, VEGF blockers alone may be inadequate and, therefore,
work on blocking mutant genes that avoid growth-inhibitions mecha
nisms and investigation on genes that may cause cell death or
apoptosis are being done. Similarly, Genentech has genetically
engineered Herceptin to repress HER 2 protein and to kill cancer
cells.
Epidermal growth factor receptors (EGFR) is important for can
cer growth.’°5Abgenix Company has manufactured a monoclonal
antibody against EGFR by injecting human EGFR into mice to
create antibodies. But when the mice antibodies are injected into
humans, the latter correctly identifies the mice antibodies as foreign
and destroys them before they can fight the cancer.
Abgenix has been able to change and disable the mice genes that
make the antibodies. Human genes are then inserted into the mice.
These human genes direct the production of human antibodies. The
result is the Xenomouse which still recognizes the human protein as
foreign, but which responds by making human antibodies accept
able to the immune system of human patients.
Adenoviruses, used to introduce p53. a tumor suppressor gene,
have been studied by Introgen Therapeutics. Many cancer cases are
COMPANY DRUGS STAGE ACTION
Genentech VEGF Antibody Final Stage Testing for AB against VEGF
lung and colon cancer protein
PharmaciaJSugen SU541 6 Final Stage Testing for Drug that blocks
colon cancer VEGF receptor
Imclone Systems IMC I Cl 1 Early Clinical Tests AB against VEGF
receptor
Astra-Zeneca AZD6474 About to begin human Drug that blocks
testing VEGF receptor
Novartis PTK-787 Early human tests on Drug that blocks
temporary hold VEGF receptor
Pharmacia! Sugen SU6668 Early human tests Drug that blocks
VEGF receptor
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missing a p53 gene or have a defective p53 gene. By the introduction
of a functional p53 gene. the cancer associated error in the DNA can
be spotted and cell suicide or apoptosis can be triggered , thereby
avoiding cancer spread.’°6
Withdrawal of Carcinogens
Elimination of carcinogens or irritants may play a role in the
regression of cancers, especially if the lesion is still in the preinva
sive stages.8’Some malignancies in the bronchial epithelium have
regressed with cessation of smoking. Preinvasive changes in uterine
cervical cancer, leukoplakia of the mouth, and carcinoma-in-situ of
the bladder or colonic polyps have also undergone regression with
removal of irritant factors.
Infection, fever, and vaccine mechanisms
One of the most prominent events mentioned in many cases has been
fever or sepsis.88’99°Infections, fever, or even vaccinations associ
ated with the cancer have wrought beneficial effects frequently
associated with the disappearance of the cancer.5”4’30279Why this
happens is unknown. In most articles, some influence on the im
mune system is mentioned as affecting the cancer.
Apoptosis, Antibody, Antiangiogenesis and
Maturation
Reasons for SR whether through apoptosis,82antibody formation,7’82
antiangiogenesis,66maturation of the undifferentiated cells,36 cyto
toxic or killing activity in the patient’s blood,5 activation of tumor
necrosis factor6’ have all been diligently studied.
Studies have suggested that interleukin-4, a cytokine produced by
mast cells and T lymphocytes. can cause growth inhibition in human
breast cancer cells by inducing apoptosis.97Programmed cell death
(apoptosis) also has been correlated with an increase of a protein
labeled BAX, whereas Bcl-2, another protein, has been shown to
inhibit apoptsis. This can be exhibited by infecting human cancer
cells with an adenovirus expressing the cancer growth suppressor
gene, mda-87.9 Apoptosis in the prostate is activated by hormone
ablation and is under the control of several regulating genes includ
ing the tumor suppressor gene p53 and the proto-oncogene bcl-2.99
Withdrawal of therapy
Bissods and Kaczmarek55 reported a case of SR of prostate cancer
after withdrawal of diethylstilbestrol therapy. Since a significant
proportion of lymphoproliferation disorders have regression of their
disease after methotrexate therapy withdrawal, Salloum, etal56 have
suggested that this fact may have important implications in the
management of lymphornas.
Natural killer activity
So-called natural killer activity has been found in the blood of
patients with lymphoma.5’renal cell cancer.’9neuroblastoma.’9and
histocytoma.54How this killing activity is initiated and the mecha
nisms through which it works have not yet been uncovered.
Endocrine factors and hormonal and pregnancy
influences
That hormones can influence breast cancer is well known.3”4’47The
role of tamoxifen. lactation, pregnancy, estrogen, and cortisone in
their influence on breast carcinomas are excellent examples of the
endocrine effect.
Prayer in spontaneous regression of cancer
Recently, Harris,68 in a randomized, controlled trial, pointed out the
positive outcomes in patients admitted to the coronary care units
affected by remote intercessory progress. This appeared to be a
confirmation of Bryd’ s study on the beneficial effects of interces
sory prayers again in a coronary care unit population. Hirschberg
and Barasch [3 1], in their recent book, suggested that optimistic,
positive attitudes and spirituality helped in cancer cures and possibly
even with SR. It would be, of course, extremely difficult to prove
conclusively a connection between prayers and SR.
In a study by Berlan,78 a large percentage of patients attributed
their recovery to their prayers and to God.
In case one of this paper, the SR was attributed, by the patient, to
the intercession of Father Damien.92 Her faith and belief in the
benefits of prayer led her to write to the Pope in Rome and to start
the process for the canonization or sainthood of Blessed Damien
when her bilateral pulmonary liposarcoma metastases all disap
peared.
In case two of this paper, the patient prayed to Buddha. According
to Tseng7°and Chan,87 prayers allowed the “chi” or vital energy to
flow unrestricted from the body and allowed the mutated cancer
cells to mature or differentiate and revert back to a normal state.
It is unknown whether prayers were used in cases 3 and 4 of this
manuscript.
Of course, the most famous story of prayers affecting cancer is
that of St. Peregrine, the patron saint of cancer.32When the latter was
a young priest, he was scheduled for an amputation because of a
cancer of his leg. The night prior to his operation, he prayed
fervently, dreamed that he was cured, and, on awakening, he was
indeed cured. He was canonized St. Peregrine in 1726.
That prayers influenced the SR’s in cases 1 and 2 described in this
manuscript can be difficult, if not impossible, to prove. Mention of
the connection between SR’s and prayers is made as part of the
discussion because of the fairly large number of writings in the
review of the literature and for the completion’s sake.94
Comment
Why SR occurred in the above 4 reported cases is unknown. Could
it be the infections or inflammation or necrosis in the first 3 cases?
The 40 case of the ruptured hepatocellular carcinoma and cirrhosis
of the liver with the emergency right hepatic lobectomy did not have
sepsis.
In the case of the metastatic pleomorphic liposarcoma. doxcycline
was injected into the left hip seroina cavity. Could it be that the
doxycline. an antibiotic synthetically derived from oxytetracycline.
behave similarly as the tetracycline given to the leukemic mice in
Huettner’s experiment.3 thereby cause a “switching off’ of the
liposcaroma proliferation’? But the doxycycline was given 6 months
before the metastases appeared.
It should be emphasized that the four cases ofSR described in this
article were well documented, well diagnosed, and histologically
proven, and without any treatment or treated inadequately to exert
a cure as in case 4 when only a emergency right hepatic lobectomy
was done and gross cancer was left in the left lobe. Yet all cases
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showed complete and permanent disappearance of all of the cancers.
Thus, they easily met the criteria as set forth by Everson and Cole.’
The author also had a fifth case of a 93-year-old mother of an
internist with painless obstructive jaundice due to a hard mass,
presumed to be a cancer, in the head of the pancreas. Because of her
age and her physical condition, only a bypass with a
choledochojejunostomy-roux-en-y was done. She survived another
10 years. Unfortunately, no biopsy of the pancreas was done and
thus, this case could not be included in this paper as an example of
SR because of the lack of histological proof.
Finally, adherence to the title and thesis of this paper would
suggest that the definition of complete spontaneous regression of
cancer be modified to state that it is the disappearance of all of a well
diagnosed malignancy in the absence of any treatment or in the
presence of therapy considered inadequate to exert a significant
influence on the neoplasm. Regressions should last at least one year.
Conclusion
Four cases of complete spontaneous regression of cancers, a review
of the literature, and a discussion of various possible mechanisms
involved in the disappearance of the malignancies were presented.
The four very rare events of SR are interesting because of the
sparsity of solid cancers with SR. The metastatic pleomorphic
liposarcoma in the lungs and the recurrent squamous cell carcinoma
of the esophagus may be the first case reports of their kind.
SR’ s may be even rarer than previously believed and the incidence
may be one per 140.000 cases of cancer rather than the one per
60,000 to 100,000 cancer cases as earlier thought.
Most SR’s have been associated with leukemias and lymphomas
and, therefore, SR’s of solid cancers are rare. The immune system
of the patients with SR’ s may have been influenced in some way by
one or more of the variously described mechanisms to enable the
body to destroy the cancers. Genetic induction and suppression of
cancers have recently been shown to play important roles in cancer.
Although immunological processes are stated in the literature to be
the most likely cause for SR, recent work has showed that genetic
mechanisms may be the more important processes as shown by
studies on gene damage, abnormal protein expressions and the
correction or inhibition of the offending protein.
Exact pathways have not yet been delineated but various theories
have been described. The mystery of SR has not yet been solved but
some secrets are beginning to be unlocked.
It may be that the pathway to cancer regressions, spontaneous or
otherwise, lies not in the “angel’s crown which is Immunity,” 103 but
rather in our genes and in the inhibition, correction, and in the
prevention of their abnormal expressions.
Finally the definition of complete spontaneous regression of
cancer was modified to state that it is the disappearance of all of a
well diagnosed malignancy in the absence of any treatment or in the
presence of therapy considered inadequate to exert a significant
influence of the neoplasm. Regressions should last at least one year.
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